Lirentelimab

Summary

Lirentelimab (CHEMBL4297878) is a phase-3 clinical-stage antibody; indicated across 10 conditions including duodenitis and urticaria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 10 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297878
Name	Lirentelimab
Type	Antibody
Max phase	3

Also known as: AK-002, Ak002, AK002, Antolimab, Lirentelimab, Monoclonal antibody ak002, LIRENTELIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
duodenitis	3	MONDO:0004627	MONDO:0004627
urticaria	2	MONDO:0005492	EFO:0005531
eosinophilic esophagitis	2	MONDO:0005361	EFO:0004232
atopic eczema	2	MONDO:0004980	EFO:0000274
atopic conjunctivitis	1	MONDO:0005642	EFO:0007141
conjunctivitis	1	MONDO:0003799	EFO:0009450
cutaneous mastocytosis	1	MONDO:0019023	EFO:1000886
digestive system disorder	1	MONDO:0004335	HP:0011024

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	4
PHASE1	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04322604	PHASE3	COMPLETED	A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT04322708	PHASE2/PHASE3	COMPLETED	A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
NCT04620811	PHASE3	COMPLETED	An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT04856891	PHASE3	COMPLETED	A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
NCT05152563	PHASE3	WITHDRAWN	A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT03436797	PHASE2	COMPLETED	A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
NCT03496571	PHASE2	COMPLETED	A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
NCT03664960	PHASE2	COMPLETED	An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT05155085	PHASE2	TERMINATED	A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
NCT05528861	PHASE2	TERMINATED	A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
NCT02808793	PHASE1	COMPLETED	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
NCT02859701	PHASE1	COMPLETED	Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants
NCT03379311	PHASE1	COMPLETED	A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
NCT04324268	PHASE1	COMPLETED	A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).